Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Arena Pharmaceuticals

Sort by

Arena Provides Updates on Carcinogenicity Issues Relating to Lorcaserin (ARNA, $1.91)

Wednesday, August 10, 2011 · 1:22 pm

Read More

Implications for Lorquess From FDA Request for Extremely Large Cardiovascular Outcomes Study for Orexigen's Contrave (ARNA, $1.31)

Sunday, June 5, 2011 · 3:38 pm

Read More

FDA Advisory Committee Vote on Lorcaserin is Negative (ARNA, $3.74)

Saturday, June 4, 2011 · 7:39 am

Read More

Trying to Define Path Forward for Lorcaserin with FDA (ARNA,$1.49)

Saturday, June 4, 2011 · 7:34 am

Read More

There are 4 reports on file.

« Back to Company Reports Index